Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kaiyang Ding

Showing results (21-30 of 50) with videos related to

Pageof 5
Sort By:
European Journal of Cancer (Oxford, England : 1990)|December 7, 2024
Anti-PD-1 antibody (Tislelizumab) combined with gemcitabine and oxaliplatin for extranodal NK/T-cell lymphoma failing asparaginase: A multicenter phase II trialKaiyang Ding, Hailing Liu, Lixia Sheng, et al.
Blood Cancer Journal|April 29, 2025
Prospective phase II trial of first-line rituximab, methotrexate, and orelabrutinib (R-MO) in primary central nervous system lymphomaLixia Sheng, Hailing Liu, Xiaohui Zhang, et al.
Haematologica|January 26, 2023
Tislelizumab with gemcitabine and oxaliplatin in patients with relapsed or refractory classic Hodgkin lymphoma: a multicenter phase II trialKaiyang Ding, Hailing Liu, Jie Ma, et al.
Chinese Medical Journal|April 10, 2023
Chidamide-BEAC plus autologous stem cell transplantation in high-risk non-Hodgkin lymphoma: a phase II clinical trialYi Xia, Li Wang, Kaiyang Ding, et al.
Zhonghua Nei Ke Za Zhi|March 2, 2016
[The curative efficacy of unrelated umbilical cord blood stem cells transplantation in intensified myeloablative conditioned patients with acute lymphoblastic leukemia]Baolin Tang, Changcheng Zheng, Huilan Liu, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|August 16, 2017
European Group for Blood and Marrow Transplantation Risk Score Predicts the Outcome of Patients with Acute Leukemia Receiving Single Umbilical Cord Blood TransplantationXiaoyu Zhu, Lulu Huang, Changcheng Zheng, et al.
Med (New York, N.Y.)|July 31, 2024
A prospective phase 2 study of combination epigenetic therapy against relapsed/refractory peripheral T cell lymphomaKaiyang Ding, Hailing Liu, Haiyan Yang, et al.
Journal of Hematology & Oncology|August 22, 2022
Revealing the evolution of the tumor immune microenvironment in follicular lymphoma patients progressing within 24 months using single-cell imaging mass cytometryLong Liu, Xingxing Yu, Zhifeng Li, et al.
BMC Cancer|May 7, 2025
Real-world analysis of treatment patterns, effectiveness, and safety of daratumumab-based regimens in Chinese patients with newly diagnosed or relapsed/refractory multiple myelomaLuqun Wang, Wei Yang, Yafei Wang, et al.
Annals of Hematology|April 12, 2026
Treatment patterns, effectiveness, and safety of daratumumab-based regimens in Chinese patients with multiple myeloma: longer follow-up of the real-world MMY4032 studyWei Yang, Luqun Wang, Yafei Wang, et al.
Pageof 5

Showing results (21-30 of 50) with videos related to

Sort By:
Pageof 5
European Journal of Cancer (Oxford, England : 1990)|December 7, 2024
Anti-PD-1 antibody (Tislelizumab) combined with gemcitabine and oxaliplatin for extranodal NK/T-cell lymphoma failing asparaginase: A multicenter phase II trialKaiyang Ding, Hailing Liu, Lixia Sheng, et al.
Blood Cancer Journal|April 29, 2025
Prospective phase II trial of first-line rituximab, methotrexate, and orelabrutinib (R-MO) in primary central nervous system lymphomaLixia Sheng, Hailing Liu, Xiaohui Zhang, et al.
Haematologica|January 26, 2023
Tislelizumab with gemcitabine and oxaliplatin in patients with relapsed or refractory classic Hodgkin lymphoma: a multicenter phase II trialKaiyang Ding, Hailing Liu, Jie Ma, et al.
Chinese Medical Journal|April 10, 2023
Chidamide-BEAC plus autologous stem cell transplantation in high-risk non-Hodgkin lymphoma: a phase II clinical trialYi Xia, Li Wang, Kaiyang Ding, et al.
Zhonghua Nei Ke Za Zhi|March 2, 2016
[The curative efficacy of unrelated umbilical cord blood stem cells transplantation in intensified myeloablative conditioned patients with acute lymphoblastic leukemia]Baolin Tang, Changcheng Zheng, Huilan Liu, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|August 16, 2017
European Group for Blood and Marrow Transplantation Risk Score Predicts the Outcome of Patients with Acute Leukemia Receiving Single Umbilical Cord Blood TransplantationXiaoyu Zhu, Lulu Huang, Changcheng Zheng, et al.
Med (New York, N.Y.)|July 31, 2024
A prospective phase 2 study of combination epigenetic therapy against relapsed/refractory peripheral T cell lymphomaKaiyang Ding, Hailing Liu, Haiyan Yang, et al.
Journal of Hematology & Oncology|August 22, 2022
Revealing the evolution of the tumor immune microenvironment in follicular lymphoma patients progressing within 24 months using single-cell imaging mass cytometryLong Liu, Xingxing Yu, Zhifeng Li, et al.
BMC Cancer|May 7, 2025
Real-world analysis of treatment patterns, effectiveness, and safety of daratumumab-based regimens in Chinese patients with newly diagnosed or relapsed/refractory multiple myelomaLuqun Wang, Wei Yang, Yafei Wang, et al.
Annals of Hematology|April 12, 2026
Treatment patterns, effectiveness, and safety of daratumumab-based regimens in Chinese patients with multiple myeloma: longer follow-up of the real-world MMY4032 studyWei Yang, Luqun Wang, Yafei Wang, et al.
Pageof 5